General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity

John B Irwin,1 AL Baldwin,2 Virgil I Stenberg31Private Practice, Tarrington, CT, USA; 2Department of Physiology, School of Medicine, University of Arizona School of Medicine, Tucson, AZ, USA; 3University of North Dakota, Grand Forks, ND, USA&dagger;John B Irwin passed away on November 3, 2015. O...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Irwin JB, Baldwin AL, Stenberg VI
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	general theory of inflammation chronic inflammation inflammation control system pain osteoarthritis fibromyalgia Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/31f3c6d282c0495c9879bd56f99dd892
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:31f3c6d282c0495c9879bd56f99dd892
record_format	dspace
spelling	oai:doaj.org-article:31f3c6d282c0495c9879bd56f99dd8922021-12-02T07:53:30ZGeneral theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity1178-7031https://doaj.org/article/31f3c6d282c0495c9879bd56f99dd8922019-06-01T00:00:00Zhttps://www.dovepress.com/general-theory-of-inflammation-patient-self-administration-of-hydrocor-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031John B Irwin,1 AL Baldwin,2 Virgil I Stenberg31Private Practice, Tarrington, CT, USA; 2Department of Physiology, School of Medicine, University of Arizona School of Medicine, Tucson, AZ, USA; 3University of North Dakota, Grand Forks, ND, USA&dagger;John B Irwin passed away on November 3, 2015. Objective: To determine if patient self-administration of hydrocortisone will safely achieve superior symptom control for all hydrocortisone-responding disorders as it does for Addison’s disease and rheumatoid arthritis.Methods: Two thousand four hundred and twenty-eight participants with hydrocortisone-responding disorders were brought to a minimum symptom state using daily administered hydrocortisone tablets in a 24-week, open study. Thereafter, participants used 5-day, low-dose hydrocortisone regimens to quench subsequent disorder exacerbations (flares) to maintain the minimum symptom state. Stressors such as emotional traumas, infections, allergies, and injuries were minimized to reduce disorder intensity, hydrocortisone consumption, and participant discomfort.Results: Two thousand fifteen participants, 601 with fibromyalgia, 579 with osteoarthritis, 246 with rheumatoid arthritis, 226 with undifferentiated arthritis, 75 with back pain, 51 with Parkinson’s disease, 44 with polymyalgia rheumatica, 25 with neuropathy, 25 with chronic fatigue syndrome, 25 with dementia, 21 with migraine headache, 19 with multiple sclerosis, and 78 with other disorders completed the 24-week study to achieve a composite average symptom improvement of 76% with equal response rates. The participants averaged ingesting 12 mg of hydrocortisone per day. No significant adverse reactions were observed.Conclusions: Patient self-administration of hydrocortisone safely achieves superior symptom control for 38 hydrocortisone-responding disorders at equal rates and symptom improvements to confirm and amplify an earlier double-blind study finding on rheumatoid arthritis. These results are consistent with the body having an inflammation control system and chronic inflammation being a disorder unto itself with differing symptoms sets dependent on its location.Clinical Trials Government Identifier: NCT03558971Keywords: general theory of inflammation, chronic inflammation, inflammation control system, pain, osteoarthritis, fibromyalgiaIrwin JBBaldwin ALStenberg VIDove Medical Pressarticlegeneral theory of inflammationchronic inflammationinflammation control systempainosteoarthritisfibromyalgiaPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 12, Pp 161-166 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	general theory of inflammation chronic inflammation inflammation control system pain osteoarthritis fibromyalgia Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	general theory of inflammation chronic inflammation inflammation control system pain osteoarthritis fibromyalgia Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Irwin JB Baldwin AL Stenberg VI General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity
description	John B Irwin,1 AL Baldwin,2 Virgil I Stenberg31Private Practice, Tarrington, CT, USA; 2Department of Physiology, School of Medicine, University of Arizona School of Medicine, Tucson, AZ, USA; 3University of North Dakota, Grand Forks, ND, USA&dagger;John B Irwin passed away on November 3, 2015. Objective: To determine if patient self-administration of hydrocortisone will safely achieve superior symptom control for all hydrocortisone-responding disorders as it does for Addison’s disease and rheumatoid arthritis.Methods: Two thousand four hundred and twenty-eight participants with hydrocortisone-responding disorders were brought to a minimum symptom state using daily administered hydrocortisone tablets in a 24-week, open study. Thereafter, participants used 5-day, low-dose hydrocortisone regimens to quench subsequent disorder exacerbations (flares) to maintain the minimum symptom state. Stressors such as emotional traumas, infections, allergies, and injuries were minimized to reduce disorder intensity, hydrocortisone consumption, and participant discomfort.Results: Two thousand fifteen participants, 601 with fibromyalgia, 579 with osteoarthritis, 246 with rheumatoid arthritis, 226 with undifferentiated arthritis, 75 with back pain, 51 with Parkinson’s disease, 44 with polymyalgia rheumatica, 25 with neuropathy, 25 with chronic fatigue syndrome, 25 with dementia, 21 with migraine headache, 19 with multiple sclerosis, and 78 with other disorders completed the 24-week study to achieve a composite average symptom improvement of 76% with equal response rates. The participants averaged ingesting 12 mg of hydrocortisone per day. No significant adverse reactions were observed.Conclusions: Patient self-administration of hydrocortisone safely achieves superior symptom control for 38 hydrocortisone-responding disorders at equal rates and symptom improvements to confirm and amplify an earlier double-blind study finding on rheumatoid arthritis. These results are consistent with the body having an inflammation control system and chronic inflammation being a disorder unto itself with differing symptoms sets dependent on its location.Clinical Trials Government Identifier: NCT03558971Keywords: general theory of inflammation, chronic inflammation, inflammation control system, pain, osteoarthritis, fibromyalgia
format	article
author	Irwin JB Baldwin AL Stenberg VI
author_facet	Irwin JB Baldwin AL Stenberg VI
author_sort	Irwin JB
title	General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity
title_short	General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity
title_full	General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity
title_fullStr	General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity
title_full_unstemmed	General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity
title_sort	general theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/31f3c6d282c0495c9879bd56f99dd892
work_keys_str_mv	AT irwinjb generaltheoryofinflammationpatientselfadministrationofhydrocortisonesafelyachievessuperiorcontrolofhydrocortisonerespondingdisordersbymatchingdosagewithsymptomintensity AT baldwinal generaltheoryofinflammationpatientselfadministrationofhydrocortisonesafelyachievessuperiorcontrolofhydrocortisonerespondingdisordersbymatchingdosagewithsymptomintensity AT stenbergvi generaltheoryofinflammationpatientselfadministrationofhydrocortisonesafelyachievessuperiorcontrolofhydrocortisonerespondingdisordersbymatchingdosagewithsymptomintensity
_version_	1718399092398227456

General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity

Ejemplares similares